Earlier this week, the European Commission approved Merck’s ENFLONSIA (clesrovimab), a long-acting monoclonal antibody to ...

Regeneron and Telix announced a strategic radiopharma collaboration worth up to $4.3 billion. Daiichi Sankyo entered a $1.55 ...

Merck , known as MSD outside of the United States and Canada, announced today that the European Commission (EC) has approved ENFLONSIAtm (clesrovimab) for the prevention of respiratory syncytial virus ...

The Merck update, which will shed light on a $588 million bet to succeed Keytruda, is part of a roster of presentations that ...

Over the last 30 years, scientists have experimented with ways to harness plant biology to create medications, or even deliver vaccines to animals and humans — but the science has moved away from ...

In this week’s edition of InnovationRx, we look at the top self-made healthcare entrepreneurs, the latest 30 Under 30 Science ...

Several shots – including flu and Covid – lost their CDC recommendations under overhauls from the White House ...

FDA reversal, patent relief, and mRESVIA risks show a commoditized market and lofty $20B valuation. See more here.

ETHealthworld.com brings latest daiichi sankyo news, views and updates from all top sources for the Indian Health industry.

The POLITICO Poll made a stark finding last month in a survey of more than 3,800 Americans about a variety of health issues: ...

Merck (NYSE:MRK) is a global leader in healthcare and pharmaceuticals, contributing significantly to the Russell 1000 Index.

During the pharma earnings season, which begins on Tuesday, Novo Nordisk will report the first revenue numbers from an oral ...